ALZAI Health Corp. Posted for Trading On The Frankfurt Stock Exchange
TORONTO, ONTARIO – September 3, 2026 – ALZAI Health Corp. (TSXV: ALZI) (FRA: H2F) (“ALZAI” or the “Company”), a healthcare technology company developing artificial intelligence-driven disease risk identification solutions, is pleased to announce that its common shares are now posted for trading on the Frankfurt Stock Exchange (“FSE”) under the symbol H2F. The Frankfurt Stock […]
ALZAI Health Corp. Announces Marketing Services Agreement
Toronto, Ontario – August 17, 2026 — ALZAI Health Corp. (TSXV: ALZI) (the “Company” or “ALZAI”) announces that it has entered into a services agreement dated August 12, 2026 (the “Services Agreement”) with Euro Digital Media Ltd. (“Euro Digital”) (address: 71-75 Shelton Street, Covent Garden, London, UK WC2H 9JQ) pursuant to which Euro Digital will […]
ALZAI and Linus Health explore AI-driven collaborations aimed at early identification of Alzheimer’s disease risk and cognitive impairment
TORONTO, ONTARIO AND BOSTON, MASSACHUSETTS – August 11, 2026 – ALZAI Health Corp. (TSXV: ALZI) is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with Linus Health, an AI-driven brain health company focused on early detection and proactive intervention. The companies intend to explore opportunities to use their complementary technologies […]
ALZAI Health Corp. Secures Exclusive Global License for AI-Driven Liver Disease Risk Identification Technology
Toronto, Ontario–(July 20, 2026) – ALZAI Health Corp. (TSXV: ALZI) (“ALZAI” or the “Company”), is pleased to announce that it has entered into an exclusive worldwide license agreement (the “Agreement”) with MOR Research Applications Ltd. (“MOR”), the technology transfer company of Clalit Health Services and Yeda Research, the technology transfer company of the Weizmann Institute […]
ALZAI HEALTH CORP. ANNOUNCES VALIDATION OF ITS AI-DRIVEN ALZHEIMERS DISEASE RISK SCREENING SOLUTION ON LARGE-SCALE U.S. PATIENT DATA
TORONTO, ONTARIO – [DATE], 2026 – ALZAI Health Corp. (TSXV: ALZI) (“ALZAI” or the “Company”), is pleased to announce the validation of its proprietary artificial intelligence-driven Alzheimer’s disease risk identification models using a large-scale U.S. longitudinal healthcare dataset, representing a significant milestone in the Company’s potential U.S. commercialization. The validation demonstrated that ALZAI’s risk-stratification models […]
ALZAI HEALTH CORP. SIGNS STRATEGIC U.S. COMMERCIALIZATION AGREEMENT WITH CENTAURI HEALTH SOLUTIONS TO ADVANCE AI-DRIVEN ALZHEIMER’S RISK IDENTIFICATION
TORONTO, ONTARIO – July 2, 2026 – ALZAI Health Corp. (TSXV: ALZI) (“ALZAI” or the “Company”), is pleased to announce that it has entered into a strategic teaming agreement (the “Agreement”) with Centauri Health Solutions (“Centauri”), a leading U.S. healthcare technology company serving 60 million members through advanced mission-critical technology, data intelligence, and engagement solutions […]
ALZAI HEALTH CORP. ANNOUNCES TSX VENTURE EXCHANGE LISTING
Not for distribution to U.S. Newswire services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. VANCOUVER, BRITISH COLUMBIA, June 8, 2026 – Alzai Health Corp. (“Alzai” or the “Corporation”), further to its press release dated April 22, 2026, is pleased to […]
ALZAI HEALTH CORP. FILES FINAL PROSPECTUS IN CONNECTION WITH INITIAL PUBLIC OFFERING
Not for distribution to U.S. Newswire services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. April 22, 2026 – Toronto, Ontario – Alzai Health Corp. (TSXV: ALZI) (“Alzai” or the “Corporation”) is pleased to announce that it has obtained a […]